Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Forward Clinical Trials Inc

Neither a doctor nor a teaching hospital

Research payments

$14,107,640

1,015 payments

Through program year 2025, Forward Clinical Trials Inc is reported as receiving $14,107,640 in research payments, across 1,015 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $961,401 84
2024 Research $1,269,035 97
2023 Research $814,980 122
2022 Research $2,797,773 184
2021 Research $3,098,689 200
2020 Research $2,415,628 137
2019 Research $2,750,134 191

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $7,249,878 208 payments
  2. Janssen Research & Development, LLC $2,151,136 180 payments
  3. AbbVie, Inc. $1,570,305 204 payments
  4. Pfizer Inc. $1,143,157 179 payments
  5. Ucb SA $821,044 17 payments
  6. Moderna TX, Inc. $442,688 29 payments
  7. Regeneron Pharmaceuticals, Inc. $255,261 124 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $158,812 37 payments
  9. Dermira, Inc. $127,261 11 payments
  10. UCB Biosciences Inc. $97,891 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2a2b Multi Center Randomized Placebo and Active Comparator controlled Double Blind Dose ranging Study to Evaluate the Safety and Efficacy of Bermekimab JNJ77474462 for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa. $1,199,270 30 payments
  2. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $906,737 12 payments
  3. A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines $690,252 21 payments
  4. A Phase 2B, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa $617,101 2 payments
  5. A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $507,687 5 payments
  6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3041658 in Adults With Moderate-To-Severe Hidradenitis Suppurativa $503,360 5 payments
  7. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $442,688 29 payments
  8. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $429,908 5 payments
  9. A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis. $410,969 2 payments
  10. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $379,243 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record